Currently, Health Canada grants exemptions that allow for individual therapy sessions using psilocybin for the terminally ill. The new clinic will start with this mandate, but Harder hopes to see it expand.
Psychedelic medicine biotech firm MindMed has announced it has begun a study for a “neutralizer” technology that could shorten and stop the effects of an LSD trip during therapy, paving the way for an “emergency shut-off switch” for psychedelic-assisted therapy.
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazonian basin. DMT can also be synthesised in a laboratory.
MindMed has several therapies based on lysergic acid diethylamide (LSD) in the phase 2 for treatment of anxiety and cluster headaches, which would be used as an aid during therapy sessions.
Psychedelics are going mainstream. Not only is the US FDA supportive of research, dozens of medical studies are proving such treatments could be helpful, including Johns Hopkins Medicine and New York University. In research to date, psilocybin has been found to help treat mental health issues, such as depression, anxiety, obsessive-compulsive disorder, and PTSD. LSD may be able to help patients with alcohol addiction and other mental disorders. MDMA-assisted therapy could help treat eating disorders, including anorexia and binge eating.
Numinus Announces Milestones in Compassionate Access Trial for MDMA Assisted Therapy in Collaboration with MAPS Public Benefit Corporation
Numinus Announces Milestones in Compassionate Access Trial for MDMA [...]
Universal Ibogaine Chairman Shayne Nyquvest joined Steve Darling from Proactive with news the company is planning to hold a conference Feb 19-20 with experts from all over the world calling it an Ibogaine Master Class.
California Would Legalize Possession Of Psychedelics Like LSD, DMT And Psilocybin Under New Senate Bill
Possession of psychedelics such as psilocybin mushrooms, LSD and DMT would be legalized in California under a new Senate bill that was introduced on Wednesday.
MindMed is one of those companies. The Toronto-based firm is led by JR Rahn, a former Uber executive whose cocaine addiction led him to try psychedelics as a treatment—an experience he credits with saving his life. Rahn believes drugs like LSD could hold the key to helping the millions of people who have been driven to despair by the pandemic.
LSD may alter consciousness by freeing the brain from its natural barriers, allowing neurons that wouldn't normally interact, to have unusual conversations, brain scans show.